ide-cel

Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
Sat, 12/26/20 - 08:27 pm
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Pharmaforum
Tue, 12/22/20 - 10:41 am
JNJ
Janssen
Multiple Myeloma
CAR-T
cilta-cel
FDA
Bristol-Myers Squibb
ide-cel
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Tue, 09/22/20 - 12:18 pm
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Thu, 07/30/20 - 12:01 am
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Thu, 05/14/20 - 10:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Motley Fool
Wed, 05/13/20 - 11:21 am
Bristol-Myers Squibb
Bluebird Bio
refusal to file letter
FDA
ide-cel
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Tue, 03/31/20 - 10:47 am
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
Sat, 12/7/19 - 11:47 pm
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel